Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET

Company Participants

Olivia Manser - Director, IR

Christian Itin - CEO

Lucinda Crabtree - CFO

Conference Call Participants

Mara Goldstein - Mizuho

Rob Andrews - William Blair

Bill Jahangiri - Truist

Gil Blum - Needham & Company

Kelly Shi - Jefferies

Chuan Hong - JPMorgan

Operator

Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Second Quarter 2022 Financial Results Conference Call. As a reminder, this conference call is being recorded. [Operator Instructions]

Without further ado, I would like now to turn the conference over to your host, Olivia Manser, Director, Investor Relations. Olivia?

Olivia Manser

Thanks, Gory. Good morning or good afternoon, everyone, and thank you for joining us to take part in today's call on the financial results and operational highlights for the second quarter of 2022. I'm Olivia Manser, Director of Investor Relations. And with me on the call are Dr. Christian Itin, our Chief Executive Officer; and Dr. Lucinda Crabtree, our Chief Financial Officer.

So on Slide 2, before we begin, I would just like to remind you that during today's call, our discussion will contain forward-looking statements. Please make sure you are familiar with this disclosure slide.

On Slide 3, you should see the agenda for today, which is as follows: Christian, will provide an overview of our operational highlights for the second quarter of 2022. Lucinda, will then discuss the company's financial results before Christian will conclude with the upcoming milestones and any other concluding comments, and we'll then turn over for Q&A.

I'll now hand over to Christian to begin the presentation.

Christian Itin

Thank you, Olivia, and good morning to you all, and thank you for joining us. It's my pleasure to review our progress for the second quarter in 2022.

Please move to Slide 4. For those who are new to Autolus and as a refresher for those of you who know us well, we are building a fully integrated CAR T company. Building on our broad platform of cell programming technologies, we're generating CAR T products that are tailored to the specific tumor setting we're addressing.

We had a successful quarter with multiple readouts from our clinical programs at the European Hematology Association Congress in Vienna in June, which gives us great confidence in the inherent value of our pipeline and the progress achieved. We continue to enroll patients into the pivotal FELIX trial, where we're investigating obe-cel for the treatment of relapsed/refractory adult acute lymphoblastic leukemia patients.